- Brand IP Statement(s) re: (c), (TM), (SM)
- MYO-X(TM) represents a major advancement in muscle building science.
- Brand IP Statement(s) re: (c), (TM), (SM)
- This patent pending compound, MyoT12(R), functions as a modulator and inhibitor to myostatin activity and has been validated in a clinical study to reduce serum myostatin levels an average of 46% among study subjects in just 12 to 18 hours with just a single serving.
- General Statements: All Other Content
- This is a very significant breakthrough for bodybuilders, athletes and even aging adults looking to increase muscle mass and strength. Myostatin is present in all of us and regardless of how hard you train, myostatin will limit your muscle building potential. Controlling the activity of myostatin is the key to counteracting the forces that have restricted your ability to build more muscle and will open the door to your new muscle building potential.
- Brand IP Statement(s) re: (c), (TM), (SM)
- Under exclusive license, MHP's MYO-X(TM) has emerged as the single most powerful approach to extreme muscle enhancement for all athletes!*
- Brand IP Statement(s) re: (c), (TM), (SM)
- MyoT12(R), the active ingredient in MYO-X(TM), has been shown in a clinical study to reduce serum myostatin in study subjects by an average of 46% in 12-18 hours with just a single serving!
- General Statements: All Other Content
- 100% of all human clinical test subjects showed significant reductions in myostatin. The average serum myostatin declined to 12.6 pg/ml with every subject responding positively! This was a staggering average 46% drop in myostatin from baseline across all subjects! Finally, at the 24-30 hour time point with a mean value of 28.1pg/ml, the average myostatin level completely normalized.
100% of all human test subjects showed significant reductions in myostatin.
- General Statements: All Other Content
- CLINICALLY TESTED
- Brand IP Statement(s) re: (c), (TM), (SM)
- POWERED BY
MyoT12(R)